U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 1 Neutrophil Count Decreased, CTCAE

MedGen UID:
1643395
•Concept ID:
C4685307
•
Finding

Definition

<LLN-1500/mm3; <LLN-1.5 x 10e9/L [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 1 Neutrophil Count Decreased, CTCAE

Professional guidelines

PubMed

Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients.
Hoffmann JHO, Knoop C, Schäkel K, Enk AH, Hadaschik EN
J Dermatol 2021 Jun;48(6):835-843. Epub 2021 Jan 20 doi: 10.1111/1346-8138.15754. PMID: 33470023

Recent clinical studies

Etiology

Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, Castellino SM, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R
Lancet Haematol 2022 Sep;9(9):e678-e688. Epub 2022 Jul 20 doi: 10.1016/S2352-3026(22)00168-5. PMID: 35870472Free PMC Article
Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y
Thorac Cancer 2022 Jan;13(1):117-125. Epub 2021 Nov 17 doi: 10.1111/1759-7714.14233. PMID: 34791805Free PMC Article
Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients.
Hoffmann JHO, Knoop C, Schäkel K, Enk AH, Hadaschik EN
J Dermatol 2021 Jun;48(6):835-843. Epub 2021 Jan 20 doi: 10.1111/1346-8138.15754. PMID: 33470023
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T
BMC Cancer 2016 Jul 13;16:467. doi: 10.1186/s12885-016-2491-y. PMID: 27412464Free PMC Article
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma.
Tomono A, Ito K, Hayashi T, Ando M, Ando Y, Tsuge M, Okamoto A, Inaguma Y, Okamoto M, Emi N, Yamada S
Cancer Chemother Pharmacol 2016 Aug;78(2):305-12. Epub 2016 Jun 20 doi: 10.1007/s00280-016-3076-9. PMID: 27324021Free PMC Article

Therapy

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y
Thorac Cancer 2022 Jan;13(1):117-125. Epub 2021 Nov 17 doi: 10.1111/1759-7714.14233. PMID: 34791805Free PMC Article
Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients.
Hoffmann JHO, Knoop C, Schäkel K, Enk AH, Hadaschik EN
J Dermatol 2021 Jun;48(6):835-843. Epub 2021 Jan 20 doi: 10.1111/1346-8138.15754. PMID: 33470023
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, Hynes S, Pitou C, Campbell R, Iversen P, Farrington DL, Bell-McGuinn K, Thomas M
Invest New Drugs 2020 Aug;38(4):1145-1155. Epub 2019 Nov 9 doi: 10.1007/s10637-019-00873-6. PMID: 31707688
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T
BMC Cancer 2016 Jul 13;16:467. doi: 10.1186/s12885-016-2491-y. PMID: 27412464Free PMC Article
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma.
Tomono A, Ito K, Hayashi T, Ando M, Ando Y, Tsuge M, Okamoto A, Inaguma Y, Okamoto M, Emi N, Yamada S
Cancer Chemother Pharmacol 2016 Aug;78(2):305-12. Epub 2016 Jun 20 doi: 10.1007/s00280-016-3076-9. PMID: 27324021Free PMC Article

Prognosis

Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, Castellino SM, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R
Lancet Haematol 2022 Sep;9(9):e678-e688. Epub 2022 Jul 20 doi: 10.1016/S2352-3026(22)00168-5. PMID: 35870472Free PMC Article
Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients.
Hoffmann JHO, Knoop C, Schäkel K, Enk AH, Hadaschik EN
J Dermatol 2021 Jun;48(6):835-843. Epub 2021 Jan 20 doi: 10.1111/1346-8138.15754. PMID: 33470023
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T
BMC Cancer 2016 Jul 13;16:467. doi: 10.1186/s12885-016-2491-y. PMID: 27412464Free PMC Article

Clinical prediction guides

Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
Zhu G, Wang L, Zhong S, Han S, Peng H, Tong M, He X
Eur J Drug Metab Pharmacokinet 2024 Mar;49(2):207-217. Epub 2024 Feb 21 doi: 10.1007/s13318-024-00877-5. PMID: 38381348
Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients.
Hoffmann JHO, Knoop C, Schäkel K, Enk AH, Hadaschik EN
J Dermatol 2021 Jun;48(6):835-843. Epub 2021 Jan 20 doi: 10.1111/1346-8138.15754. PMID: 33470023
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T
BMC Cancer 2016 Jul 13;16:467. doi: 10.1186/s12885-016-2491-y. PMID: 27412464Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...